Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) COVID-19 Development Update Conference Call May 19, 2020 8:10 AM ET Company Participants Joshua Reed – Chief Financial Officer Todd Brady – President and Chief Executive Officer Adam Brockman – Director-Non-Clinical Development Conference Call Participants Louise Chen – Cantor Justin Kim – Oppenheimer Yigal Nochomovitz – Citigroup Yale Jen – Laidlaw & Company Esther Hong – Janney Matthew Cross – JonesTrading Operator Ladies and gentlemen, thank you for standing by an ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q1 2020 Results Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Dr. Todd Brady - President and CEO David McMullin - Chief Commercial Officer Conference Call Participants Samantha Semenkow - Citi Carvey Leung - Cantor Esther Hong - Janney Matthew Cross - Jones Trading Operator Good morning. And welcome to the Aldeyra Therapeutics First Quarter 2020 Financial Results Conference Call. After the speaker’ remarks, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 20-1968197 (State or other jurisdiction ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Todd Brady - President & Chief Executive Officer Joshua Reed - Chief Financial Officer David McMullin - Chief Commercial Officer Conference Call Participants Louise Chen - Cantor Yigal Nochomovit - Citi Group Adam Walsh - Stifel Esther Hong - Janney I-Eh Jen - Laidlaw Matthew Cross - Jones Trading Operator Good morning and to welcome to the Aldeyra Therapeutics Full Year 2019 Financial Re ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q3 2019 Results Conference Call November 7, 2019 8:00 AM ET Company Participants Todd Brady - Chief Executive Officer Joshua Reed - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citi Investment Research Sudan Loganathan - Cantor Fitzgerald & Company Esther Hong - Janney Montgomery Scott Adam Walsh - Stifel, Nicolaus & Company Matthew Cross - JonesTrading Institutional Services Operator Good morning and to welcome to the Aldeyra Therapeutics ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other jur ...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q2 2019 Earnings Conference Call August 8, 2019 8:00 AM ET Company Participants Joshua Reed - CFO Todd Brady - CEO, President & Director Conference Call Participants Victor Rusu - Citigroup Esther Hong - Janney Montgomery Scott I-Eh Jen - Laidlaw & Company Matthew Cross - JonesTrading Institutional Services Operator Good morning. My name is Carol, and I will be your operator today. At this time, I would like to welcome everyone to the Aldeyra Therapeutics reports sec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or other ju ...